源自人类多能干细胞的工程化抗前列腺癌嵌合抗原受体中性粒细胞
Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells.
作者信息
Harris Jackson D, Chang Yun, Syahirah Ramizah, Lian Xiaojun Lance, Deng Qing, Bao Xiaoping
机构信息
Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA.
Purdue University Institute for Cancer Research. West Lafayette, IN 47907, USA.
出版信息
J Immunol Regen Med. 2023 May;20. doi: 10.1016/j.regen.2023.100074. Epub 2023 Apr 1.
Abstract
Immunotherapy is a powerful technique where immune cells are modified to improve cytotoxicity against cancerous cells to treat cancers that do not respond to surgery, chemotherapy, or radiotherapy. Expressing chimeric antigen receptor (CAR) in immune cells, typically T lymphocytes, is a practical modification that drives an immune response against cancerous tissue. CAR-T efficacy is suboptimal in solid tumors due to the tumor microenvironment (TME) that limits T lymphocyte cytotoxicity. In this study, we demonstrate that neutrophils differentiated from human pluripotent stem cells modified with AAVS1-inserted CAR constructs showed a robust cytotoxic effect against prostate-specific membrane antigen (PSMA) expressing LNCaP cells as a model for prostate cancer . Our results suggest that engineered CAR can significantly enhance the neutrophil anti-tumor effect, providing a new avenue in treating prostate cancers.
摘要
免疫疗法是一种强大的技术，通过对免疫细胞进行改造来提高其对癌细胞的细胞毒性，以治疗对手术、化疗或放疗无反应的癌症。在免疫细胞（通常是T淋巴细胞）中表达嵌合抗原受体（CAR）是一种切实可行的改造方法，可驱动针对癌组织的免疫反应。由于肿瘤微环境（TME）限制了T淋巴细胞的细胞毒性，CAR-T在实体瘤中的疗效并不理想。在本研究中，我们证明，用插入AAVS1的CAR构建体修饰的人多能干细胞分化而来的中性粒细胞，对表达前列腺特异性膜抗原（PSMA）的LNCaP细胞（作为前列腺癌模型）显示出强大的细胞毒性作用。我们的结果表明，工程化CAR可显著增强中性粒细胞的抗肿瘤作用，为治疗前列腺癌提供了一条新途径。
相似文献
1
Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells.源自人类多能干细胞的工程化抗前列腺癌嵌合抗原受体中性粒细胞
J Immunol Regen Med. 2023 May;20. doi: 10.1016/j.regen.2023.100074. Epub 2023 Apr 1.
2
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.抗 PSMA CAR 工程化 NK-92 细胞：用于前列腺癌的现成细胞疗法。
Cells. 2020 Jun 2;9(6):1382. doi: 10.3390/cells9061382.
3
Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.通过基于纳米抗体的嵌合抗原受体靶向前列腺癌细胞上前列腺特异性膜抗原的工程化人 Jurkat 细胞。
Iran Biomed J. 2020 Mar;24(2):81-8. doi: 10.29252/ibj.24.2.81. Epub 2019 Oct 23.
4
Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.用于前列腺癌免疫治疗的先进代抗前列腺特异性膜抗原设计 T 细胞。
Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.
5
High-throughput method to analyze the cytotoxicity of CAR-T Cells in a 3D tumor spheroid model using image cytometry.高通量方法使用图像细胞术分析 CAR-T 细胞在 3D 肿瘤球体模型中的细胞毒性。
SLAS Discov. 2023 Apr;28(3):65-72. doi: 10.1016/j.slasd.2023.01.008. Epub 2023 Feb 8.
6
Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.构建一种嵌合抗原受体，该受体携带针对前列腺特异性膜抗原的纳米抗体用于前列腺癌。
J Cell Biochem. 2019 Jun;120(6):10787-10795. doi: 10.1002/jcb.28370. Epub 2019 Jan 22.
7
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.多西他赛通过抑制 MDSC 增强了 PSMA 特异性 CAR-T 细胞对前列腺癌模型的治疗效果。
J Cancer Res Clin Oncol. 2022 Dec;148(12):3511-3520. doi: 10.1007/s00432-022-04248-y. Epub 2022 Aug 12.
8
Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy.从人多能干细胞工程嵌合抗原受体中性粒细胞用于靶向癌症免疫治疗。
Cell Rep. 2022 Jul 19;40(3):111128. doi: 10.1016/j.celrep.2022.111128.
9
Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.嵌合细胞因子受体增强 PSMA-CAR-T 细胞介导的前列腺癌消退。
Cancer Biol Ther. 2020 Jun 2;21(6):570-580. doi: 10.1080/15384047.2020.1739952. Epub 2020 Mar 25.
10
Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.生物共轭液态固体增强了对实体瘤 - 嵌合抗原受体 T 细胞相互作用的表征。
Acta Biomater. 2023 Dec;172:466-479. doi: 10.1016/j.actbio.2023.09.042. Epub 2023 Oct 1.
引用本文的文献
1
Neutrophil Dynamics in Response to Cancer Therapies.中性粒细胞对癌症治疗的反应动力学
Cancers (Basel). 2025 Aug 7;17(15):2593. doi: 10.3390/cancers17152593.
2
Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails.使用异硫氰酸荧光素-叶酸双特异性衔接子桥接的嵌合抗原受体免疫细胞鸡尾酒进行肿瘤免疫治疗的新策略。
Bioact Mater. 2025 Jun 18;52:529-540. doi: 10.1016/j.bioactmat.2025.06.025. eCollection 2025 Oct.
3
Designing Chimeric Antigen Receptors for Myeloid Immune Cells.设计用于髓系免疫细胞的嵌合抗原受体
J Cancer Biol Res. 2024;11(1). Epub 2024 Jun 16.
4
Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.源自培养皿的过继性细胞疗法：增强诱导多能干细胞
Transfus Med Hemother. 2024 Aug 26;52(1):27-41. doi: 10.1159/000540473. eCollection 2025 Feb.
5
Forward programming of hPSCs to neutrophils using chemically defined media.使用化学成分明确的培养基将人多能干细胞正向编程为中性粒细胞。
Stem Cell Res Ther. 2025 Feb 3;16(1):32. doi: 10.1186/s13287-025-04147-2.
6
Activated neutrophils: A next generation cellular immunotherapy.活化中性粒细胞：新一代细胞免疫疗法。
Bioeng Transl Med. 2024 Aug 13;10(1):e10704. doi: 10.1002/btm2.10704. eCollection 2025 Jan.
7
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.将诱导多能干细胞（iPSC）技术与基于嵌合抗原受体（CAR）的免疫疗法相结合：最新进展、挑战与未来前景。
Front Cell Dev Biol. 2024 Nov 18;12:1491282. doi: 10.3389/fcell.2024.1491282. eCollection 2024.
8
Novel immunotherapeutic approaches in gastric cancer.胃癌的新型免疫治疗方法。
Precis Clin Med. 2024 Sep 19;7(4):pbae020. doi: 10.1093/pcmedi/pbae020. eCollection 2024 Dec.
9
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy.新型来源的 CAR 产品：癌症免疫治疗突破的新途径。
Front Immunol. 2024 Apr 11;15:1378739. doi: 10.3389/fimmu.2024.1378739. eCollection 2024.
10
PTP1B phosphatase dampens iPSC-derived neutrophil motility and antimicrobial function.蛋白酪氨酸磷酸酶1B（PTP1B）可抑制诱导多能干细胞衍生的中性粒细胞的运动性和抗菌功能。
J Leukoc Biol. 2024 Jun 28;116(1):118-131. doi: 10.1093/jleuko/qiae039.
本文引用的文献
1
Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy.从人多能干细胞工程嵌合抗原受体中性粒细胞用于靶向癌症免疫治疗。
Cell Rep. 2022 Jul 19;40(3):111128. doi: 10.1016/j.celrep.2022.111128.
2
Chemically-defined generation of human hemogenic endothelium and definitive hematopoietic progenitor cells.化学定义的人类造血内皮细胞和确定性造血祖细胞的生成。
Biomaterials. 2022 Jun;285:121569. doi: 10.1016/j.biomaterials.2022.121569. Epub 2022 May 6.
3
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC).转移性去势抵抗性前列腺癌（mCRPC）的现有及新兴疗法
Biomedicines. 2021 Sep 17;9(9):1247. doi: 10.3390/biomedicines9091247.
4
CAR-macrophage: A new immunotherapy candidate against solid tumors.嵌合抗原受体巨噬细胞：一种针对实体瘤的新型免疫疗法候选药物。
Biomed Pharmacother. 2021 Jul;139:111605. doi: 10.1016/j.biopha.2021.111605. Epub 2021 Apr 23.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
The Chimeric Antigen Receptor Detection Toolkit.嵌合抗原受体检测工具包。
Front Immunol. 2020 Aug 11;11:1770. doi: 10.3389/fimmu.2020.01770. eCollection 2020.
7
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.抗 PSMA CAR 工程化 NK-92 细胞：用于前列腺癌的现成细胞疗法。
Cells. 2020 Jun 2;9(6):1382. doi: 10.3390/cells9061382.
8
Human chimeric antigen receptor macrophages for cancer immunotherapy.用于癌症免疫疗法的人嵌合抗原受体巨噬细胞。
Nat Biotechnol. 2020 Aug;38(8):947-953. doi: 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.
9
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.增强嵌合抗原受体 T 细胞在实体瘤中的疗效。
Clin Cancer Res. 2020 Jun 1;26(11):2444-2451. doi: 10.1158/1078-0432.CCR-19-1835. Epub 2020 Feb 3.
10
Effective and Rapid Generation of Functional Neutrophils from Induced Pluripotent Stem Cells Using ETV2-Modified mRNA.利用 ETV2 修饰 mRNA 从诱导多能干细胞中有效快速生成功能性中性粒细胞。
Stem Cell Reports. 2019 Dec 10;13(6):1099-1110. doi: 10.1016/j.stemcr.2019.10.007. Epub 2019 Nov 7.
Zotero 插件